About Phosphatidylinositol 4-kinase alpha
Phosphatidylinositol 4-kinase alpha (PI4KA) is a protein
from Homo sapiens identified by UniProt accession
P42356, 2102 residues long.
MolForge cross-references it against 0 known binders and
125 disease associations.
Target properties
| Protein name | Phosphatidylinositol 4-kinase alpha |
| UniProt accession | P42356 |
| Gene | PI4KA |
| Organism | Homo sapiens |
| Length | 2102 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (125)
Diseases linked to this target (Open Targets).
- bilateral perisylvian polymicrogyria · score 0.74
- spastic paraplegia 84, autosomal recessive · score 0.58
- neurodegenerative disease · score 0.49
- CEDNIK syndrome · score 0.49
- heparin cofactor 2 deficiency · score 0.47
- multiple intestinal atresia · score 0.38
- hypomyelinating leukodystrophy 2 · score 0.33
- hemorrhage · score 0.27
- glioblastoma multiforme · score 0.25
- monocyte count · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P42356-F1 | alphafold | PREDICTED | 79.71 | — |
Amino-acid sequence (2102 residues)
MAAAPARGGG GGGGGGGGCS GSGSSASRGF YFNTVLSLAR SLAVQRPASL EKVQKLLCMC PVDFHGIFQL DERRRDAVIA LGIFLIESDL QHKDCVVPYL LRLLKGLPKV YWVEESTARK GRGALPVAES FSFCLVTLLS DVAYRDPSLR DEILEVLLQV LHVLLGMCQA LEIQDKEYLC KYAIPCLIGI SRAFGRYSNM EESLLSKLFP KIPPHSLRVL EELEGVRRRS FNDFRSILPS NLLTVCQEGT LKRKTSSVSS ISQVSPERGM PPPSSPGGSA FHYFEASCLP DGTALEPEYY FSTISSSFSV SPLFNGVTYK EFNIPLEMLR ELLNLVKKIV EEAVLKSLDA IVASVMEANP SADLYYTSFS DPLYLTMFKM LRDTLYYMKD LPTSFVKEIH DFVLEQFNTS QGELQKILHD ADRIHNELSP LKLRCQANAA CVDLMVWAVK DEQGAENLCI KLSEKLQSKT SSKVIIAHLP LLICCLQGLG RLCERFPVVV HSVTPSLRDF LVIPSPVLVK LYKYHSQYHT VAGNDIKISV TNEHSESTLN VMSGKKSQPS MYEQLRDIAI DNICRCLKAG LTVDPVIVEA FLASLSNRLY ISQESDKDAH LIPDHTIRAL GHIAVALRDT PKVMEPILQI LQQKFCQPPS PLDVLIIDQL GCLVITGNQY IYQEVWNLFQ QISVKASSVV YSATKDYKDH GYRHCSLAVI NALANIAANI QDEHLVDELL MNLLELFVQL GLEGKRASER ASEKGPALKA SSSAGNLGVL IPVIAVLTRR LPPIKEAKPR LQKLFRDFWL YSVLMGFAVE GSGLWPEEWY EGVCEIATKS PLLTFPSKEP LRSVLQYNSA MKNDTVTPAE LSELRSTIIN LLDPPPEVSA LINKLDFAMS TYLLSVYRLE YMRVLRSTDP DRFQVMFCYF EDKAIQKDKS GMMQCVIAVA DKVFDAFLNM MADKAKTKEN EEELERHAQF LLVNFNHIHK RIRRVADKYL SGLVDKFPHL LWSGTVLKTM LDILQTLSLS LSADIHKDQP YYDIPDAPYR ITVPDTYEAR ESIVKDFAAR CGMILQEAMK WAPTVTKSHL QEYLNKHQNW VSGLSQHTGL AMATESILHF AGYNKQNTTL GATQLSERPA CVKKDYSNFM ASLNLRNRYA GEVYGMIRFS GTTGQMSDLN KMMVQDLHSA LDRSHPQHYT QAMFKLTAML ISSKDCDPQL LHHLCWGPLR MFNEHGMETA LACWEWLLAG KDGVEVPFMR EMAGAWHMTV EQKFGLFSAE IKEADPLAAS EASQPKPCPP EVTPHYIWID FLVQRFEIAK YCSSDQVEIF SSLLQRSMSL NIGGAKGSMN RHVAAIGPRF KLLTLGLSLL HADVVPNATI RNVLREKIYS TAFDYFSCPP KFPTQGEKRL REDISIMIKF WTAMFSDKKY LTASQLVPPD NQDTRSNLDI TVGSRQQATQ GWINTYPLSS GMSTISKKSG MSKKTNRGSQ LHKYYMKRRT LLLSLLATEI ERLITWYNPL SAPELELDQA GENSVANWRS KYISLSEKQW KDNVNLAWSI SPYLAVQLPA RFKNTEAIGN EVTRLVRLDP GAVSDVPEAI KFLVTWHTID ADAPELSHVL CWAPTDPPTG LSYFSSMYPP HPLTAQYGVK VLRSFPPDAI LFYIPQIVQA LRYDKMGYVR EYILWAASKS QLLAHQFIWN MKTNIYLDEE GHQKDPDIGD LLDQLVEEIT GSLSGPAKDF YQREFDFFNK ITNVSAIIKP YPKGDERKKA CLSALSEVKV QPGCYLPSNP EAIVLDIDYK SGTPMQSAAK APYLAKFKVK RCGVSELEKE GLRCRSDSED ECSTQEADGQ KISWQAAIFK VGDDCRQDML ALQIIDLFKN IFQLVGLDLF VFPYRVVATA PGCGVIECIP DCTSRDQLGR QTDFGMYDYF TRQYGDESTL AFQQARYNFI RSMAAYSLLL FLLQIKDRHN GNIMLDKKGH IIHIDFGFMF ESSPGGNLGW EPDIKLTDEM VMIMGGKMEA TPFKWFMEMC VRGYLAVRPY MDAVVSLVTL MLDTGLPCFR GQTIKLLKHR FSPNMTEREA ANFIMKVIQS CFLSNRSRTY DMIQYYQNDI PY
Explore Phosphatidylinositol 4-kinase alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets